Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30251350 | 1.00 | TAAR1 (0.69) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL18448337 | 0.98 | TAAR1 (0.67) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL31019690 | 0.98 | TAAR1 (0.67) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL3903774 | 0.87 | TAAR1 (0.53) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL6547406 | 0.85 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6PYCR1ALDH1A1 | |
| SCHEMBL8910791 | 0.85 | TAAR1 (0.52) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL11331960 | 0.84 | TAAR1 (0.50) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL11329915 | 0.84 | TAAR1 (0.50) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL11329871 | 0.84 | TAAR1 (0.50) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 | |
| SCHEMBL11337231 | 0.84 | TAAR1 (0.50) | TAAR1HTR2AHTR1DCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-12552748-B2 | Pyridine (thio)amides as fungicidal compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-17 | — | — | US | disclosed |
| US-20250064060-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4426677-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-118265702-A | Microbiocidal isonicotinamide derivatives | 先正达农作物保护股份公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240182420-A1 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | US | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | TAAR1 3775/4885HTR2A 2748/4885HTR1D 4095/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | TAAR1 1932/4885HTR2A 1200/4885HTR1D 216/4885 |
| US-20250064060-A1 | BIS(HETERO)ARYL THIOETHER (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | TST, TPMT, NAT1 | TAAR1 277/4885HTR2A 3382/4885HTR1D 3629/4885 |
| US-12552748-B2 | Pyridine (thio)amides as fungicidal compounds | CBR1, CBR3, TH | TAAR1 448/4885HTR2A 4211/4885HTR1D 1269/4885 |
| US-20240182420-A1 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | ARG2, MPO, ARG1 | TAAR1 1728/4885HTR2A 3913/4885HTR1D 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.